UCB's Global Corporate Website
Welcome to UCB in the United States
Jan 07
Katelyn Snider, U.S. Communications and Public Affairs
Growing our Footprint in Boston and Seattle

In 2019, we look forward to continuing our journey to grow our impact. Our future has never been brighter and the opportunities to provide patients with solutions they value has never been more urgent. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, solutions are on the horizon to help more patients managing severe diseases live their best lives.

To help us on this mission, we’ve welcomed employees from our 2017 Beryllium acquisition into the UCB family. This development contributes to a 15% growth in new colleagues at UCB in the U.S. – bringing our U.S. team to approximately 1,300 employees—and grows our presence in Boston, Massachusetts and Seattle, Washington. These new teams will be boosting UCB’s capabilities in protein engineering and structural biology, and building new platform capabilities to drive our existing and future discovery pipeline.

As we jump start the new year, our dedication to research and development remains unchanged through investing about a quarter of our global revenue to cutting-edge scientific research to meet unmet patient needs. We believe, as long as there are unmet needs, our mission continues, and we look forward to the progress on the horizon for patients in 2019 and the years to come.

Share:linkedin| twitter| email